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Abstract 
 
Objectives: To investigate a possible association between autonomic dysfunction and 
fatigue in people with multiple sclerosis. 
 
Methods: In 70 people with multiple sclerosis early in the disease course (51 females, mean 
age 33.89.1) quantitative sudomotor axon reflex test, cardiovascular reflex tests (heart rate 
and blood pressure responses to Valsalva maneuver and heart rate response to deep 
breathing) and the tilt table test were performed. Participants completed the Composite 
Autonomic System Score-31, Modified Fatigue Impact, Beck Depression and Epworth 
Sleepiness scales. Cut-off scores of ≥38 or ≥45 on the Modified Fatigue Impact Scale were 
used to stratify patients into a fatigued subgroup (N=17 and N=9, respectively). 
 
Results: We found clear association between fatigue and subjective tests of the autonomic 
nervous system: fatigued patients scored significantly worse on Composite Autonomic 
System Score-31 and there was strong correlation between Modified Fatigue Impact Scale 
and Composite Autonomic System Score-31 (rs =0.607, p<0.001). On the other hand, we 
found only modest association between fatigue and objective tests of the autonomic 
nervous system: there was a clear trend of lower sweating outputs on all measure sites, 
reaching statistical significance for distal leg and foot. We found weak correlations between 
Modified Fatigue Impact Scale and Valsalva ratio (rs =-0.306, p=0.011), Modified Fatigue 
Impact Scale and quantitative sudomotor axon reflex test of the forearm, proximal and distal 
lower leg (rs =-0.379, p=0.003, rs =-0.356, p=0.005 and rs =-0.345, p=0.006, respectively). A 
multiple regression model showed that Composite Autonomic System Score-31, Beck 
depression scale and Epworth Sleepiness Scale were independent predictors of fatigue 
(p=0.005, p=0.019 and p=0.010, respectively). 
 
Conclusion: These results suggest that people with multiple sclerosis, already early in their 
disease course, suffer from objective and subjective impairments of the autonomic nervous 
system and suggest an association between autonomic nervous system impairment and 
multiple sclerosis related fatigue.  
 
Key words: Fatigue, depression, sleep, multiple sclerosis  
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Introduction 
 
Fatigue is one of the most common symptoms of many neurological conditions and it is 
defined as extreme and persistent mental and/or physical tiredness, weakness or exhaustion 
(1). It can be primary, when it is considered to be part of the underlying neurological 
condition, or secondary, when it results from the presence of other concomitant 
circumstances or diseases (2). 
Fatigue is one of the most frequent and the most burdensome symptoms of multiple 
sclerosis (MS) (3). Multiple sclerosis related fatigue (MSRF) is reported in up to 80% of the 
people with MS (pwMS), and over 55% of patients report fatigue as the worst symptom 
experienced from MS (4). Several MS specific processes may be responsible for primary 
MSFR, like impaired interactions between functionally related cortical and subcortical areas, 
activation of proinflammatory cytokines and dysregulation of the neuroendocrine system (5, 
6, 7). However, a substantial proportion of pwMS also have concomitant depression and 
sleep disorders, which are strongly related to secondary MSRF (8, 9). 
It has recently been suggested that the dysregulation of the autonomic nervous system 
(ANS) can lead to many MS-related clinical symptoms/comorbidities, including fatigue, 
depression and sleep disorders (10). Also, it has been demonstrated that ANS dysfunction is 
frequent in MS and it is present even in the earliest stages of the disease, with 
parasympathetic dysfunction present in 5 %, sympathetic in 42.6 % and sudomotor in 32.7 % 
of patients (11). 
With the hypothesis that ANS dysfunction is an important contributor to MSRF, we aimed to 
investigate the role of ANS dysfunction in MSRF, taking into consideration the presence of 
depression and sleep disorders. 
 
 
Methods 
 
Patients who participated in the BACIS project (12), in which consecutive patients with CIS 
were recruited into a two-year prospective clinical and neurophysiological follow-up from 
October 2014 until April 2016, were asked to participate in an MS comorbidities substudy at 
month 24 visit. All patients signed informed consent and the study was approved by Ethical 
Committees of the University Hospital Center Zagreb and the University of Zagreb, School of 
Medicine. 
During the month 24 visit, testing of the ANS was performed. It consisted of Quantitative 
Sudomotor Axon Reflex Test (QSART) performed with Q-Sweat (WR Medical Electronics Co 
Maplewood, MN, USA) (13), testing of cardiovascular reflexes (heart rate and blood pressure 
responses to Valsalva maneuver and heart rate response to deep breathing) and the tilt 
table test (Task Force Monitor (TFM), CNSystems Medizintechnik AG, Austria) (13,14). 
Composite Autonomic Scoring Scale (CASS) was utilized to quantify autonomic dysfunction 
(15).  
Following ANS testing, 70 participants filled in validated Croatian versions of the Composite 
Autonomic System Score-31 (COMPASS-31) (16), the Modified Fatigue Impact Scale (MFIS), 
the Beck depression scale (BDI-2) and Epworth Sleepiness Scale (ESS) (17). Clinically relevant 
BDI-2 result was considered if the score was >18 (18). 
Previous studies have used cut-off scores of ≥38 or ≥45 on the MFIS to define fatigue, so in 
our analysis, we used both cut-off points in order to stratify patients into a fatigued 
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subgroup (N=17 and N=9, respectively) and a non-fatigued subgroup (N=53 and N=61, 
respectively) (19,20). For each participant, Expanded Disability Status Scale (EDSS) and 
current use of disease modifying therapy (DMT) was noted.  
The primary objective was to evaluate differences in ANS tests and COMPASS-31, BDI-2 and 
ESS between fatigued and non-fatigued subgroups.  
Secondary outcomes were to correlate MFIS with objective tests of ANS function and 
subjective measures of dysautonomia (COMPASS-31), depression (BDI-2) and daytime 
sleepiness (ESS). 
Finally, in order to examine the influence of age, sex, depression, daytime sleepiness, 
autonomic symptom burden and current use of DMT on the fatigue measured with MFIS, a 
multiple linear regression model was used.  
 
Statistical analysis 
Statistical analysis was performed using the IBM SPSS software, version 20. The 
Kolmogorov–Smirnov test was applied to test whether the data has a normal distribution. 
Differences in the distribution of qualitative variables were determined with the χ2 test 
(sex), while the differences in quantitative variables were determined with the use of 
parametric t test (age, respiratory sinus arrhythmia (RSA), Valsalva ratio (VR), QSART results) 
or nonparametric Mann–Whitney (EDSS, CASS, ESS, BDI-2, COMPASS-31). To determine the 
correlation between the MFIS variable and other variables (age, RSA, VR, QSART, COMPASS-
31, CASS, ESS, BDI-2, EDSS) the Spearman correlation method was used. Multiple linear 
regression model based on six predictors (age, sex, depression defined as BDI-2 score >18, 
ESS, total sum of COMPASS-31 and current use of DMT) was used in order to determine 
significant predictors for the presence of fatigue measured with MFIS and its subtypes 
(physical fatigue, cognitive fatigue and psychosocial fatigue). Also, additional regression 
analysis for every domain of COMPASS-31 was performed with previously mentioned 
predictors in the model. For the predictors in multiple regression models, p values less than 
0.05 were considered as significant. For analysis that included more comparisons on the 
same set of data, p values corrected with Bonferroni correction were considered as 
significant. 
 
Results 
 
Baseline patients’ characteristics are presented in table 1. Thirty-five (50%) patients were on 
DMTs (7 on teriflunomide, 8 on dimethyl fumarate, 6 on interferon beta, 13 on glatiramer 
acetate and 1 on alemtuzumab). 
 
Descriptive measures for patients with and without fatigue 
 
Differences in all studied parameters between fatigued and non-fatigued MS patients 
defined either as MFIS ≥45 or ≥38 are presented in table 2. Fatigued patients according to 
the both cut-off values were older and scored significantly worse on BDI-2 and COMPASS-31. 
There was a clear trend of lower sweating outputs an all measure sites, reaching statistical 
significance for distal leg (MFIS ≥45) and foot (MFIS≥38).   
 
Correlations of subjective and objective ANS tests 
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Results of the correlation between parameters of objective autonomic nervous system 
testing and different domains of COMPASS-31 are presented in Supplementary table 1. 
There was statistically significant correlation between the RSA and bladder domain of the 
COMPASS-31 (rs =-0.358, p=0.002) and between QSART of the proximal leg and 
gastrointestinal domain (rs =-0.383, p=0.002), QSART of the distal leg and secretomotor 
domain (rs =-0.394, p=0.002) and QSART of the distal leg and the gastrointestinal domain (rs 
=-0.381, p=0.002). 
 
Correlations of fatigue with objective and subjective ANS tests, depression and daytime 
sleepiness 
 
We found significant correlations between MFIS and age (rs=0.329, p=0.005), MFIS and VR (rs 
=-0.306, p=0.011), MFIS and QSART of the forearm, proximal and distal lower leg (rs =-0.379, 
p=0.003, rs =-0.356, p=0.005 and rs =-0.345, p=0.006, respectively) (Figure 1), MFIS and BDI-2 
(rs =0.756, p<0.001), and MFIS and COMPASS-31 (rs =0.607, p<0.001) (Figure 2). Also, there 
was statistically significant correlation between the MFIS and every domain of COMPASS-31 
(orthostatic intolerance, rs =0.426, p<0.001; vasomotor, rs =0.387, p=0.001; secretomotor, rs 
=0.409, p<0.001; gastrointestinal, rs =0.503, p<0.001; bladder, rs =0.433, p<0.001; 
pupilomotor, rs =0.720, p<0.001). 
 
Regression analysis 
 
A multiple regression model was used to predict the presence of fatigue measured with the 
MFIS based on age, sex, depression defined as BDI-2 score >18, daytime sleepiness 
measured with ESS, autonomic dysfunction measured with COMPASS-31 and current use of 
DMT. Multiple regression model statistically significantly predicts the MFIS variable 
(F=11.366, p<0.001), with a R2=0.536. Total sum of COMPASS-31, BDI-2 and ESS were 
independent predictors for the presence of fatigue measured with the MFIS (B=0.464, 
p=0.005, B=17.344, p=0.019 and B=1.111, p=0.01, respectively). As MFIS can distinguish 
different types of fatigue (physical, cognitive and psychosocial) we further analysed 
influence of the studied parameters on these three types of MSRF. There was statistically 
significant correlation between the age and cognitive fatigue (rs =0.295, p=0.013). Results of 
the regression analysis with different types of fatigue (physical, cognitive and psychosocial) 
as outcome variables are presented in Table 3. The only statistically significant predictor for 
cognitive fatigue was COMPASS-31, while statistically significant predictors for physical 
fatigue were ESS, BDI-2 and COMPASS-31. 
Finally, in order to examine the possible influence of age, sex, depression defined as BDI-2 
score >18, ESS, different domains of the COMPASS-31 and current use of DMT on the fatigue 
measured with MFIS the regression analysis was performed (Supplementary table 2). The 
regression analysis showed that that orthostatic intolerance and bladder domains of the 
COMPASS-31 were not statistically significant independent predictors of MFIS, while other 
domains (vasomotor, secretomotor, gastrointestinal and pupilomotor) were. 
 
Discussion 
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We have found that pwMS who suffer from fatigue score significantly worse on COMPASS-
31, a patient-related outcome evaluating autonomic symptoms. Furthermore, COMPASS-31 
independently predicted fatigue, regardless of depression and/or daytime sleepiness. 
Several studies used different objective tests of ANS in order to investigate possible role of 
ANS dysfunction in development of MSRF. Initial studies focused on correlation of different 
tests of cardiovascular autonomic function (heart rate and blood pressure variability, 
responses to postural changes, pressure tests, the Valsalva maneuver, deep breathing, and 
hyperventilation), and were largely negative, or if positive, confounded by age effects on 
autonomic tests (21,22). In one study, the consistent decrease of blood pressure response to 
sustained grip in combination with increased fatigue was observed (23). Our study 
confirmed these observations, as we were unable to show differences in any of the studied 
cardiovascular reflexes between fatigued and non-fatigued patients. 
On the other hand, we found clear association between MSRF and subjective measures of 
ANS dysfunction. Since the introduction of COMPASS-31, it has become possible to 
systematically assess quantitative autonomic symptoms. One of the initial studies 
investigating the relationship of autonomic symptom burden to quality of life, fatigue and 
other established disease parameters was performed by Cortez and colleagues (24). This 
study has shown that autonomic symptom burden is correlated with decreased quality of life 
and increased fatigue, despite the fact that out of 100 enrolled patients, only 41 completed 
COMPASS-31 questionnaire in full. Furthermore, this study did not address possible 
covariates of fatigue like depression or daytime sleepiness, nor did authors test whether 
obtained results are still significant after using multivariate regression analysis. Another 
study showed that COMPASS-31 predicts the level of cognitive fatigue independent of age, 
disease duration, EDSS, and mental impairment (25). We have confirmed this finding in our 
study, showing that the COMPASS-31 is the only independent predictor of cognitive fatigue. 
Furthermore, we have replicated the finding that the pupillomotor domain of the COMPASS-
31 is an important contributor to the MSRF. A recent study investigating cognition and 
fatigue using pupillary responses to light, found a tendency toward a smaller pupillary 
response in pwMS with fatigue, possibly explaining observation of this association (26).  
One thing that can explain the association between MSRF and subjective dysautonomia and 
lack of association between MSRF and objective dysautonomia is discrepancy between 
patient reported symptoms and laboratory findings in structural disorders of the ANS. In line 
with this, one study has shown that even patients with severe orthostatic hypotension can 
be completely asymptomatic (27). Similarly, when we correlated domains of the COMPASS-
31 and results of the cardiovascular reflexes and QSART, we only observed significant 
correlations between QSART results and gastrointestinal and secretomotor domains of the 
COMPASS-31, suggesting that this dissociation in subjective and objective dysautonomia 
may be pertinent to MS, as well.  
Pathophysiology of MSRF is very complex, and the role of structural or functional brain 
abnormalities, the contribution of neurochemical imbalance, neuroendocrine dysfunction, 
neuroimmune dysregulation and peripheral nervous system contribution, have all been 
explored in in the generation of this symptom (28). 
Several of these hypotheses are interesting regarding the possible role of autonomic 
nervous system dysfunction in MSRF. The presence of immunological dysregulation is the 
basis of MS, and inflammatory and neuroendocrine factors may differentially mediate 
fatigue (29). Recently it has been suggested that pathologic interactions between the 
immune and the autonomic systems may fail to trigger anti-inflammatory mechanisms, 
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which are essential to prevent repeated inflammatory attacks, a key pathogenic feature of 
MS (30). The parasympathetic part of the ANS has a major role in alerting the central 
nervous system about the presence of inflammation via inflammatory cytokines (31). These 
afferent signals are transmitted by the vagal nerve and trigger an anti-inflammatory 
response, termed “cholinergic anti-inflammatory pathway” (30).  
Peripheral nervous system contribution to MSRF is a controversial topic, however it has 
been suggested that sensory perception resulting from a complex integration of 
physiological, biochemical, and other sensory feedback from the periphery may contribute 
to MSRF (32). Interestingly, we found a significant negative correlation between MFIS result 
and sweat volume on different sites measured with QSART. QSART has been traditionally 
used as a marker of peripheral cholinergic postganglionic nerve affection, and thus its value 
was mainly in the diagnosis of small fiber neuropathy. As MS is a central nervous system 
disorder, results of our study can be interpreted in two ways: either QSART can detect 
central disorders of thermoregulation or peripheral nervous system is also affected in MS. 
An argument for the former is a study that showed that QSART values can be abnormal even 
with preganglionic lesions (33). An argument for the latter came from several studies 
questioning whether MS is a pure central nervous system disorder. Jende and colleagues 
have demonstrated peripheral nerve lesions in pwMS in vivo by high resolution MRI (34). 
These lesions are defined by an increase of proton-spin-density and a decrease of T2-
relaxation time, indicating changes in the microstructural organization of the extracellular 
matrix in peripheral nerve tissue in MS. Furthermore, it has also been suggested that pwMS 
may exhibit significant small fiber damage, which is associated with neurological disability 
from MS (35, 36). One of the main consequences of sudomotor dysfunction in MS is heat 
sensitivity, and it has been suggested that heat sensitivity in MS might contribute to 
premature fatigue either through passively induced rises in body temperature or through 
exercise (37). The results of our study give a possible pathophysiological explanation of this 
association, although we did not asses changes in body temperature in the presented 
patient group. Despite this theoretical background, the relationship between fatigue 
symptoms and dysautonomia in MS received minor interest. 
The limitations of this study are possible selection bias as not all participants of the BACIS 
project participated in the substudy. It has to be emphasized that we enrolled a specific 
group of pwMS very early in the disease course and that the percentage of patients with 
fatigue was comparatively low. Furthermore, not all participants had QSART performed due 
to financial limitations. Finally, ESS measures daytime sleepiness, a similar feeling as fatigue, 
however a recent study has shown that ESS was significantly associated with sleepiness, 
tiredness, and lack of energy, but not fatigue (38). 
Despite of this, the results of this study suggest an association between autonomic 
dysfunction, especially sudomotor dysfunction and fatigue in MS patients.  Further studies 
with long term follow-up are warranted.    
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Tables 
 
Table 1. Baseline patients’ characteristics. 
 
 
Mean/median Standard 
deviation 
Range 
Age (years) 33.8 9.1  
Sex (females) 51   
EDSS 1.0  0-4.0 
Scales 
MFIS 22  0-70 
ESS 5  0-18 
BDI-2 4  0-50 
COMPASS-31 8.5  0-57.7 
OI 0  0-32 
Vasomotor 0  0-4.2 
Secretomotor 0  0-6.4 
GI 2.7  0-13.4 
Bladder 0  0-7.8 
Pupillomotor 1  0-4.0 
ANS tests 
VR 2.2 0.5  
RSA 21.9 8.2  
QSART forearm (µl)* 0.885 0.727  
QSART proximal lower leg 
(µl)* 
1.099 0.805  
QSART distal lower leg (µl)* 1.425 0.942  
QSART foot (µl)* 0.597 0420  
CASS total* 1  0-5 
CASS adrenergic 0  0-3 
CASS cardiovagal 0  0-1 
CASS sudomotor* 0  0-3 
*QSART results were available for 62 patients. 
EDSS – expanded disability status scale, COMPASS-31 - Composite Autonomic System Score-
31, OI – orthostatic intolerance; GI – gastrointestinal; MFIS - Modified Fatigue Impact Scale, 
BDI-2 - Beck depression scale, ESS - Epworth Sleepiness Scale (ESS), VR – Valslava ratio, RSA – 
respiratory sinus arrhythmia, QSART - Quantitative Sudomotor Axon Reflex Test; CASS - 
Composite autonomic scoring scale  
 13 
Table 2. Differences in all studied parameters between fatigued and non-fatigued MS 
patients defined either as MFIS ≥45 or ≥38. 
 MFIS<45 MFIS≥45 p MFIS<38 MFIS≥38 p 
Age (years)# 32.3±7.8 44.4±11.2 <0.001 31.6±7.5 40.8±10.6 <0.001 
Sex (females) 43 8 0.43 36 15 0.13 
EDSS# 1 2 0.06 1 1.5 0.10 
 Scales  
ESS# 5 6 0.51 5 11 0.009 
BDI-2# 2.5 20.5 <0.001 2 16 <0.001 
COMPASS-31* 6.5913 38.2579 0.001 6.1786 24.8016 <0.001 
OI* 0 16 0.01 0 16 0.007 
Vasomotor* 0 0 0.009 0 0 0.008 
Secretomotor* 0 4.2857 0.001 0 4.2857 0.002 
GI* 2.6786 6.2500 <0.001 1.7857 5.3571 0.001 
Bladder* 0 2.2222 0.001 0 1.1111 0.002 
Pupillomotor* 1 2.3333 <0.001 1 2.0000 <0.001 
 ANS tests  
VR# 2.3±0.5 1.8±0.3 0.03 2.3±0.5 2.0±0.3 0.04 
RSA# 22.5±8.3 17.9±6.5 0.14 23.0±8.6 18.3±5.4 0.02 
QSART forearm (µl)** 0.94±0.75 0.52±0.44 0.131 1.02±0.77 0.50±0.38 0.013 
QSART proximal lower 
leg (µl)** 
1.15±0.83 0.78±0.53 0.202 1.23±0.87 0.74±0.44 0.030 
QSART distal leg (µl)** 1.25 0.64 0.009 1.56±0.96 1.06±0.82 0.060 
QSART foot (µl)** 0.64±0.43 0.37±0.23 0.075 0.68±0.44 0.37±0.25 0.001 
CASS total** 1 2 0.07 1 2 0.045 
CASS 
adrenergic** 
0 0.5 0.53 0 1 0.10 
CASS 
cardiovagal** 
0 0 0.46 0 0 0.26 
CASS 
sudomotor** 
0 1 0.07 0 1 0.20 
* Bonferroni corrected p-value = 0.007; # Bonferroni corrected p-value = 0.017; ** 
Bonferroni corrected p-value = 0.013; Bold indicates statistically significant difference. 
EDSS – expanded disability status scale, COMPASS-31 - Composite Autonomic System Score-
31, OI – orthostatic intolerance; GI – gastrointestinal; MFIS - Modified Fatigue Impact Scale, 
BDI-2 - Beck depression scale, ESS - Epworth Sleepiness Scale (ESS), VR – Valslava ratio, RSA – 
respiratory sinus arrhythmia, QSART - Quantitative Sudomotor Axon Reflex Test; CASS - 
Composite autonomic scoring scale 
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Table 3. Regression analysis with different types of fatigue (physical, cognitive and 
psychosocial) as outcome variables. 
Predictor B P value 
Model with cognitive fatigue, (F=6.874, p<0.001), with a R2=0.411 
Sex -1.011 0.620 
Age 0.069 0.530 
Use of DMT -0.995 0.585 
ESS 0.353 0.113 
BDI-2 6.034 0.114 
COMPASS-31* 0.216 0.012 
Model with physical fatigue, (F=13.516, p<0.001), with a R2=0.579 
Sex 0.137 0.936 
Age 0.044 0.630 
Use of DMT -1.275 0.402 
ESS* 0.645 0.001 
BDI-2* 7.500 0.020 
COMPASS-31* 0.219 0.003 
Model with psychosocial fatigue, (F=13.938, p<0.001), with a R2=0.586 
Sex 0.216 0.608 
Age 0.010 0.675 
Use of DMT -0.320 0.396 
ESS* 0.142 0.003 
BDI-2* 2.647 0.001 
COMPASS-31* 0.045 0.011 
 
COMPASS-31 - Composite Autonomic System Score-31, BDI-2 - Beck depression scale, ESS - 
Epworth Sleepiness Scale (ESS), DMT – disease modifying therapy; *statistically significant 
predictor  
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Figures 
 
 
Figure 1. Correlations between Modified Fatigue Impact Scale (MFIS) and Quantitative 
Sudomotor Axon Reflex Test (QSART) of the forearm, proximal lower leg, distal lower leg and 
foot (rs= -0.379, p=0.003, rs= -0.356, p=0.005, rs= -0.345, p=0.006 and rs= -0.249, p=0.051, 
respectively; Bonferroni corrected p-value = 0.0125) 
 
 
Figure 2. Correlation between Modified Fatigue Impact Scale (MFIS) and Composite 
Autonomic System Score-31 (COMPASS-31) (rs=0.607, p<0.001; Bonferroni corrected p-value 
= 0.007) 
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